Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort
| Image |  |
|---|---|
| Description | article by Antonella d'Arminio Monforte et al published April 2018 in HIV Clinical Trials |
| Author/s | |
| Publication date | April 2018 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |